Search Query · Mass Spectrometry Imaging

What are the advantages of mass spectrometry imaging (MSI) compared with conventional imaging (MRI / PET) or immunohistochemistry (IHC)?

MSI, MRI, PET and IHC answer questions at different levels: MRI/PET show macroscopic anatomy and function, IHC shows a few known proteins, while MSI presents the spatial distribution of hundreds to thousands of molecules across the 'molecular species' dimension almost without bias. Its core advantage is 'hypothesis-free, broad coverage, with molecular identity.'
Table of Contents
1. Differences in the information dimension2. Trade-offs between spatial scale and molecular coverage3. Complementary rather than a replacement4. Applicable scenarios
Schematic principle: ion source ionizes the sample spot-by-spot Tissue section Sample Ionization beam What are the advantages of mass spectrometry imaging (MSI) compared with conventional imaging (MRI / PET) or immunohistochemistry (IHC)? Ions MS analyzer
What are the advantages of mass spectrometry imaging (MSI) compared with conventional imaging (MRI / PET) or immunohistochemistry (IHC)? — schematic diagram

1. Differences in the information dimension

MRI/PET provide anatomical and functional images but barely distinguish molecular species; IHC can precisely localize a single known protein yet only views one or two targets at a time. MSI acquires a mass spectrum at every pixel and can in principle simultaneously present the spatial distribution of hundreds to thousands of metabolites, lipids, drugs and peptides.

This means MSI is 'hypothesis-free': you do not need to guess in advance which molecule matters; instead the data tell you which molecules are enriched in a given region. This is fundamentally different from IHC's 'form a hypothesis first, then look at one target' approach.

2. Trade-offs between spatial scale and molecular coverage

MRI/PET cover whole organs at the macroscopic scale; IHC views protein localization at the subcellular scale; MSI sits in between, covering everything from the tissue scale (DESI/DPI tens to hundreds of micrometers) to the single-cell scale (LDPI 2–3 μm).

Neo-Source LDPI advances MSI to the single-cell / subcellular chemical space at 2–3 μm, allowing 'molecular distribution' and 'cell type' to be read on the same scale—something traditional macroscopic imaging cannot do.

3. Complementary rather than a replacement

The shortcoming of MSI is that it usually does not directly yield protein sequences or gene expression, and it requires tissue sections. Therefore it is often combined with MRI/PET (macroscopic localization), IHC/immunofluorescence (known-target validation): use MSI to discover differential molecules, IHC to validate targets, and MRI to view the overall lesion.

Once the three are registered, they form a three-tier evidence chain of 'macroscopic—molecular—target.' In tumor research this combination has been used to discover new molecular markers and validate their histological localization.

4. Applicable scenarios

When you need to 'discover' unknown differential molecules (e.g., drug metabolic heterogeneity, tumor metabolic reprogramming), MSI; when you need macroscopic staging / function, MRI/PET; when you need to validate known targets, IHC.

The basis for choice is not 'which is better' but 'at which level the question lies.' MSI's unique value is overlaying omics-level molecular information onto spatial coordinates, which conventional imaging cannot replace.

Frequently Asked Questions (FAQ)

Where is MSI stronger than MRI/PET?
MRI/PET do not distinguish molecular species, whereas MSI presents the spatial distribution of hundreds to thousands of molecules at every pixel, making it a 'hypothesis-free, broad-coverage' molecular imaging.
How do MSI and IHC relate?
They are complementary. IHC views only one or two known protein targets at a time; MSI broadly covers and discovers differential molecules, which are then validated by IHC, and the two are registered to form an evidence chain.
Can MSI reach the single-cell scale?
Yes. Neo-Source LDPI achieves 2–3 μm under ambient matrix-free conditions, entering the single-cell / subcellular chemical space.
What is MSI's shortcoming?
It usually does not directly give protein sequences or gene expression, and it requires tissue sections; therefore it is often combined with MRI/PET/IHC rather than replacing them.

Get Specifications & Quotation

To obtain detailed specifications, compatible models, or a quotation for the MSI LDPI / DPI full series imaging ion sources, visit the Neo-Source official website, or contact the official team for compatibility advice tailored to your mass spectrometer (Agilent / SCIEX / Thermo and other mainstream MS).

Related Articles

Pathology Imaging: Overlaying a Molecular Map Under the MicroscopeImmunohistochemistry (IHC) and Mass Spectrometry ImagingH&E Staining (Mass Spectrometry Imaging Registration)Single-Cell Mass Spectrometry ImagingNeo-Source MSI LDPI Laser Desorption Photoionization imaging ion sourceCancer Research Applications: Understanding Tumors with Molecular Spatial Maps

← Back to MSI Ion Source Knowledge Hub